Additionally, in the liver, GLT8D2 can positively regulate the expression of the ApoB100 protein in hepatocytes, promote the stable secretion of very low density lipoprotein and reduce the accumulation of triglycerides in hepatocytes, thus reducing the incidence of non-alcoholic fatty liver disease (NAFLD) (53). Here, GLT8D2 is linked to metabolic dysfunction-associated steatotic liver disease.